End-stage rheumatoid arthritis: specific features of patient management

Abstract

The paper provides data on the treatment of patients with end-stage rheumatoid arthritis (RA) and a rationale for the long-term treatment with disease-modifying antirheumatic drugs, including leflunomide as a first-line agent. It describes a clinical case of a patient with end-stage RA during arava treatment.

Keywords

• rheumatoid arthritis
• end stage
• disease-modifying antirheumatic drugs
• leflunomide